These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17522860)

  • 1. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.
    Butterfield LH; Ribas A; Potter DM; Economou JS
    Cancer Immunol Immunother; 2007 Dec; 56(12):1931-43. PubMed ID: 17522860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients.
    Evdokimova VN; Liu Y; Potter DM; Butterfield LH
    J Immunother; 2007; 30(4):425-37. PubMed ID: 17457217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma.
    Ritter M; Ali MY; Grimm CF; Weth R; Mohr L; Bocher WO; Endrulat K; Wedemeyer H; Blum HE; Geissler M
    J Hepatol; 2004 Dec; 41(6):999-1007. PubMed ID: 15582134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.
    Butterfield LH; Ribas A; Dissette VB; Lee Y; Yang JQ; De la Rocha P; Duran SD; Hernandez J; Seja E; Potter DM; McBride WH; Finn R; Glaspy JA; Economou JS
    Clin Cancer Res; 2006 May; 12(9):2817-25. PubMed ID: 16675576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of ex vivo peripheral and intrahepatic α-fetoprotein-specific CD4+ responses in hepatocellular carcinoma.
    Witkowski M; Spangenberg HC; Neumann-Haefelin C; Büttner N; Breous E; Kersting N; Drognitz O; Hopt UT; Blum HE; Semmo N; Thimme R
    Int J Cancer; 2011 Nov; 129(9):2171-82. PubMed ID: 21170957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
    Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
    Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer.
    Liu Y; Daley S; Evdokimova VN; Zdobinski DD; Potter DM; Butterfield LH
    J Immunol; 2006 Jul; 177(1):712-21. PubMed ID: 16785570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
    Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
    Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of alpha-fetoprotein-specific CD4- and CD8-mediated T-cell response using RNA-transfected dendritic cells.
    Zhang HM; Zhang LW; Ren J; Fan L; Si XM; Liu WC
    Cell Immunol; 2006 Feb; 239(2):144-50. PubMed ID: 16814271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy.
    Pan CC; Huang ZL; Li W; Zhao M; Zhou QM; Xia JC; Wu PH
    Chin J Cancer; 2010 Jun; 29(6):596-602. PubMed ID: 20507732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma.
    Palmer DH; Midgley RS; Mirza N; Torr EE; Ahmed F; Steele JC; Steven NM; Kerr DJ; Young LS; Adams DH
    Hepatology; 2009 Jan; 49(1):124-32. PubMed ID: 18980227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients.
    Alisa A; Ives A; Pathan AA; Navarrete CV; Williams R; Bertoletti A; Behboudi S
    Clin Cancer Res; 2005 Sep; 11(18):6686-94. PubMed ID: 16166448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.
    Butterfield LH; Economou JS; Gamblin TC; Geller DA
    J Transl Med; 2014 Apr; 12():86. PubMed ID: 24708667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity.
    Wang X; Wang Q
    Can J Gastroenterol Hepatol; 2018; 2018():9049252. PubMed ID: 29805966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma.
    Nakagawa H; Mizukoshi E; Kobayashi E; Tamai T; Hamana H; Ozawa T; Kishi H; Kitahara M; Yamashita T; Arai K; Terashima T; Iida N; Fushimi K; Muraguchi A; Kaneko S
    Gastroenterology; 2017 May; 152(6):1395-1406.e10. PubMed ID: 28188748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
    Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
    Front Immunol; 2020; 11():623. PubMed ID: 32425926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine.
    Bei R; Mizejewski GJ
    Curr Mol Med; 2011 Oct; 11(7):564-81. PubMed ID: 21707514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific CD8(+ )T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination.
    Zhang HG; Chen HS; Peng JR; Shang XY; Zhang J; Xing Q; Pang XW; Qin LL; Fei R; Mei MH; Leng XS; Chen WF
    Cancer Immunol Immunother; 2007 Dec; 56(12):1945-54. PubMed ID: 17522859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
    Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.